Viatris enters the final stretch of September with an unusual combination: fresh analyst enthusiasm from multiple firms, a stock that has quietly added 5% over the past month, and short sellers who appear to be retreating in size.
The analyst story is the most compelling angle this week. Oppenheimer initiated coverage on September 23 with an Outperform rating and a $25 target — nearly 45% above the current price of $17.18. That follows Leerink Partners' Outperform initiation on September 9 with a $20 target, and Argus Research lifting its Buy target from $15 to $20 on September 8. Three initiations or upgrades in two weeks is an unusual cluster. The consensus sits at Buy, with a mean target of $19.40. Piper Sandler is the outlier, maintaining Neutral while nudging its target from $12 to $13 on September 16 — a raise that still implies the stock is fairly valued at best. The bull case centres on Viatris's global generics reach across 165 countries and pipeline expansion in dermatology and ophthalmology. The bear case is well-worn: patent cliffs on Lipitor and Viagra, a fragmented portfolio that never quite gelled post-Mylan merger, and an uncertain biosimilar pipeline.
Short sellers have been unwinding positions aggressively, and the scale of the move deserves attention. Short interest fell nearly 22% over the past month, from roughly 49 million shares to 38.2 million — now equal to just 3.3% of the free float. That drop coincided with the stock's recovery from mid-August weakness and the wave of incoming analyst coverage. Borrowing conditions reflect how relaxed positioning has become: availability is extremely loose at 2,615%, meaning there are far more shares available to lend than are currently borrowed. Cost to borrow ticked up 13% on the week to 0.56%, its highest reading in the 30-day window, but that figure remains firmly in "easy borrow" territory. There is no squeeze dynamic here. The ORTEX short score of 37.7 — steady across the past two weeks — corroborates the picture: short positioning in Viatris is neither extreme nor deteriorating.
Options traders are leaning decidedly bullish. The put/call ratio dropped to 0.26 on September 22, more than 1.6 standard deviations below its 20-day mean of 0.27. That reading is close to the low end of the 52-week range, where the floor is 0.13 and the ceiling is 0.74. The contrast with late August is sharp: through most of August, the PCR ran near 0.46, reflecting genuine hedging demand. That defensive posture has largely unwound since the short interest collapsed and analysts turned constructive, leaving options positioning now skewed toward call exposure.
The institutional picture adds weight to the bull side. FMR LLC recently amended its Schedule 13G to disclose an 11% stake — up from 8.3% — having filed twice since August. That reflects meaningful buying by Fidelity's funds in recent months. T. Rowe Price added 4 million shares in the most recent reporting period and holds nearly 6% of shares outstanding. Davis Selected Advisers trimmed slightly, from 6.8% to 6.5%, but remains a top-four holder. No activist 13D is present — all large holders file passive 13G schedules — and stakes are as last disclosed, with the usual caveat that holders dropping below 5% may not file again. Insider activity is light and unremarkable: the most recent open-market sale on record was a 10b5-1 plan sale by Paul Campbell in June, worth roughly $810,000. There is no evidence of conviction selling by senior management.
On valuation, Viatris trades at roughly 6.6x trailing earnings and 7.3x EV/EBITDA — undemanding multiples for a company with stable cash generation. The forward EPS momentum factor ranks in the 92nd percentile of its universe, suggesting analysts expect earnings to grow meaningfully year-over-year. The dividend score ranks in the 84th percentile, though the dividend history in the data trails off after 2022, so current yield should be confirmed independently. The next earnings print is scheduled for November 6, and the most recent result — August 6 — saw the stock fall nearly 7% on the day and lose 9% over the following five trading sessions. That reaction is a material data point: analyst enthusiasm and a recovering stock price do not automatically translate into a clean earnings response.
The November 6 report is therefore the next clean test of whether the Street's growing conviction survives contact with the income statement.
See the live data behind this article on ORTEX.
Open VTRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
